First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
Key Clinical Summary
- The first systematic review and meta-analysis of histotripsy for liver tumors found high technical success (94.1%) and an acceptable safety profile across 10 clinical studies involving 553 patients.
- Long-term oncologic outcomes remain uncertain, with overall survival reported in only 2 studies comprising 77 patients.
- Larger prospective studies with longer follow-up and standardized assessment are needed to validate findings.
Introduction
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence. The study, authored by Wehrle CJ et al, was published in the May 2026 issue of eClinicalMedicine, an open-access journal in The Lancet Discovery Science portfolio.1
Study Findings
In this systematic review and meta-analysis, investigators searched PubMed (National Institutes of Health), Embase (Elsevier), and Scopus (Elsevier) from database inception through December 2025—along with manual review—to evaluate safety and outcomes after histotripsy for primary and secondary liver tumors.
The analysis included 10 studies comprising 553 patients. The pooled technical success rate was 94.1%. The pooled major complication rate was 7.0%. Radiologic outcomes included a pooled absence of nodular enhancement of 89.3%, a mean tumor volume reduction of 49.4%, and an off-target effect rate of 10.0%.
While no significant publication bias for mortality or safety outcomes was present, the authors noted that conclusions regarding any bias should be interpreted cautiously because of the relatively few studies available for analysis. They also reported substantial inconsistencies in the methods by which radiologic outcomes were evaluated across the included studies.
Clinical Implications
The findings support histotripsy as an emerging liver-directed therapy with high technical feasibility and encouraging early safety and radiologic outcomes. However, the current evidence base remains limited by the small number of studies, heterogeneous outcome definitions and imaging assessment, and short follow-up. Notably, overall survival was only reported up to 6 months, and this was only in 2 studies (77 patients).
Based on their assessment using the IDEAL framework for surgical innovation, the authors place histotripsy in the "late assessment of the early exploration phase. They also emphasize the importance of conducting larger multicenter prospective studies with standardized criteria and outcome measures before the role of histotripsy in routine clinical practice can be fully established.
Conclusions
This systematic review and meta-analysis suggests that histotripsy is a technically feasible liver tumor treatment with encouraging early clinical results. However, interpretation of the findings should be made with caution given the heterogeneity, small sample size, and relatively short follow-up of the included studies. Standardized prospective research with longer follow-up is needed to better define clinical outcomes.
Reference
1. Wehrle CJ, Lee J, Ahmed AS, et al. Histotripsy for liver tumours: a systematic review and meta-analysis of current clinical evidence. EClinicalMedicine. 2026;95:103926. doi:10.1016/j.eclinm.2026.103926
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Vascular Disease Management or HMP Global, their employees, and affiliates.
